世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

欧州の神経血管デバイス／インターベンショナル・ニューロロジー市場予測 2023-2032

欧州の神経血管デバイス／インターベンショナル・ニューロロジー市場予測 2023-2032


EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET FORECAST 2023-2032

主な調査結果 欧州の神経血管機器/介入神経学市場は、2023年から2032年の予測期間中にCAGR 5.01％で成長すると評価されている。老年人口が脳卒中や血管障害のような神経疾患に罹患しやすいこと、特にサービスが... もっと見る

　

　

出版社 出版年月 電子版価格 納期 ページ数 言語
Inkwood Research
インクウッドリサーチ 		2023年8月4日 US$1,600
シングルユーザライセンス（印刷不可）
ライセンス・価格情報
注文方法はこちら 		2-3営業日以内 152 英語

　

サマリー

主な調査結果
欧州の神経血管機器/介入神経学市場は、2023年から2032年の予測期間中にCAGR 5.01％で成長すると評価されている。老年人口が脳卒中や血管障害のような神経疾患に罹患しやすいこと、特にサービスが行き届いていない地域や地方における遠隔診察や遠隔医療サービスの登場が、この地域の市場成長を促進する上位要因の一つとなっている。
市場洞察
欧州の神経血管装置/介入神経学市場成長評価では、英国、スペイン、ポーランド、ベルギー、ドイツ、フランス、イタリア、その他欧州の調査を対象としている。フランス政府は、てんかん、アルツハイマー病、パーキンソン病などの特定の神経疾患への対応において、さまざまな国家的イニシアティブを通じて大きな前進を遂げている。これらのイニシアチブは、これらの疾患の研究、診断、治療を進めると同時に、患者やその家族への支援を提供することを目的としている。
重要な試みは、フランスのインサームが2023年に開始する予定のニューロテクノロジーズ・プログラムを含むブースター・プログラムである。政府はまた、基礎神経科学研究、トランスレーショナル・リサーチ、臨床試験を含む脳研究を推進するために多額の資金を割り当てている。さらにフランス政府は、国家自閉症・神経発達障害戦略へのコミットメントの一環として、自閉症・神経発達障害における119の認定研究チームのための全国学際的コンソーシアムを支援している。神経疾患患者は、神経リハビリテーション施設やプログラムへの資金提供を通じて、機能的転帰や生活の質の向上に焦点を当てた、必要不可欠なサービスを受けることができる。したがって、このような要因が、予測期間中の同地域の市場成長を促進することになる。
競合他社の洞察
市場に参入している主な企業は、Phenox Inc、Acandis GmbHなどである。
弊社のレポート提供内容は以下の通りです：
- 市場全体の主要な調査結果を探る
- 市場ダイナミクスの戦略的内訳（促進要因、抑制要因、機会、課題）
- 全セグメント、サブセグメント、地域の3年間の過去データとともに、最低9年間の市場予測
- 市場セグメンテーション：主要セグメントの徹底的な評価と市場予測
- 地域別分析：言及された地域と国レベルのセグメントを市場シェアとともに評価
- 主要分析：ポーターのファイブフォース分析、ベンダーランドスケープ、オポチュニティマトリックス、主要購買基準など。
- 競争環境は、要因や市場シェアなどに基づく主要企業の理論的説明である。
- 企業プロファイリング：詳細な会社概要、提供する製品・サービス、SCOT分析、最近の戦略的展開など


ページTOPに戻る


目次

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. GOVERNMENT INITIATIVES TO CREATE AWARENESS ABOUT NEUROVASCULAR DISEASES
2.5.2. EARLY DETECTION OF ARTERIOVENOUS MALFORMATION (AVM)
2.5.3. THROMBECTOMY IMPROVES PATIENT OUTCOMES AND REDUCES DISABILITY RATE
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SIGNIFICANT RISE IN INCIDENCE OF NEUROVASCULAR CONDITIONS
3.1.2. PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES
3.1.3. GERIATRIC POPULATION’S VULNERABILITY TO NEUROVASCULAR DISEASES
3.1.4. UNDERLYING DISEASES ARE A RISK FACTOR FOR NEUROVASCULAR DISEASES
3.2. KEY RESTRAINTS
3.2.1. EXORBITANT COSTS OF NEUROVASCULAR DEVICES
3.2.2. LACK OF TRAINED NEUROSURGEONS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR UNITED KINGDOM
4.4. MARKET CONCENTRATION ANALYSIS
4.5. VALUE CHAIN ANALYSIS
5. MARKET BY PRODUCT
5.1. EMBOLIZATION DEVICES
5.1.1. EMBOLIC COILS
5.1.1.1. COATED DETACHABLE COILS
5.1.1.2. BARE DETACHABLE COILS
5.1.2. COIL ASSIST STENT
5.1.3. CLIPPINGS
5.1.4. COIL ASSIST BALLOON
5.2. ACCESSORY DEVICES
5.2.1. MICROCATHETERS
5.2.2. MICRO GUIDEWIRES
5.3. REVASCULARIZATION DEVICES
5.3.1. CAROTID ARTERY STENTS
5.3.2. FLOW DIVERSION STENTS
5.4. THROMBECTOMY DEVICES
5.4.1. CLOT RETRIEVAL DEVICES
5.4.2. SUCTION AND ASPIRATION DEVICES
5.4.3. SNARES
5.5. EMBOLIC PROTECTION DEVICES
5.5.1. BALLOON OCCLUSION DEVICES
5.5.2. DISTAL FILTER DEVICES
6. MARKET BY APPLICATION
6.1. ANEURYSM
6.2. ISCHEMIC STROKE
6.3. STENOSIS
6.4. ARTERIOVENOUS MALFORMATION (AVM)
6.5. OTHER APPLICATIONS
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. MARKET SIZE & ESTIMATES
7.1.2. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET DRIVERS
7.1.3. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET CHALLENGES
7.1.4. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET REGULATORY FRAMEWORK
7.1.5. KEY PLAYERS IN EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET
7.1.6. COUNTRY ANALYSIS
7.1.6.1. UNITED KINGDOM
7.1.6.1.1. UNITED KINGDOM NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.2. GERMANY
7.1.6.2.1. GERMANY NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.3. FRANCE
7.1.6.3.1. FRANCE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.4. ITALY
7.1.6.4.1. ITALY NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.5. SPAIN
7.1.6.5.1. SPAIN NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.6. POLAND
7.1.6.6.1. POLAND NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.7. BELGIUM
7.1.6.7.1. BELGIUM NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.8. REST OF EUROPE
7.1.6.8.1. REST OF EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIPS & AGREEMENTS
8.1.4. BUSINESS EXPANSIONS & DIVESTITURES
8.2. COMPANY PROFILES
8.2.1. ACANDIS GMBH
8.2.1.1. COMPANY OVERVIEW
8.2.1.2. PRODUCT LIST
8.2.2. ASAHI INTECC
8.2.2.1. COMPANY OVERVIEW
8.2.2.2. PRODUCT LIST
8.2.3. BALT
8.2.3.1. COMPANY OVERVIEW
8.2.3.2. PRODUCT LIST
8.2.4. B BRAUN MELSUNGEN AG
8.2.4.1. COMPANY OVERVIEW
8.2.4.2. PRODUCT LIST
8.2.4.3. STRENGTHS & CHALLENGES
8.2.5. INTEGER HOLDINGS CORPORATION
8.2.5.1. COMPANY OVERVIEW
8.2.5.2. PRODUCT LIST
8.2.5.3. STRENGTHS & CHALLENGES
8.2.6. JOHNSON & JOHNSON (CERENOVUS)
8.2.6.1. COMPANY OVERVIEW
8.2.6.2. PRODUCT LIST
8.2.6.3. STRENGTHS & CHALLENGES
8.2.7. KANEKA CORPORATION
8.2.7.1. COMPANY OVERVIEW
8.2.7.2. PRODUCT LIST
8.2.8. MEDTRONIC INC
8.2.8.1. COMPANY OVERVIEW
8.2.8.2. PRODUCT LIST
8.2.8.3. STRENGTHS & CHALLENGES
8.2.9. MEMRY CORPORATION
8.2.9.1. COMPANY OVERVIEW
8.2.9.2. PRODUCT LIST
8.2.10. MICROPORT SCIENTIFIC CORPORATION
8.2.10.1. COMPANY OVERVIEW
8.2.10.2. PRODUCT LIST
8.2.10.3. STRENGTHS & CHALLENGES
8.2.11. PENUMBRA INC
8.2.11.1. COMPANY OVERVIEW
8.2.11.2. PRODUCT LIST
8.2.12. PHENOX INC
8.2.12.1. COMPANY OVERVIEW
8.2.12.2. PRODUCT LIST
8.2.12.3. STRENGTHS & CHALLENGES
8.2.13. RAPID MEDICAL
8.2.13.1. COMPANY OVERVIEW
8.2.13.2. PRODUCT LIST
8.2.13.3. STRENGTHS & CHALLENGES
8.2.14. SENSOME
8.2.14.1. COMPANY OVERVIEW
8.2.14.2. PRODUCT LIST
8.2.14.3. STRENGTHS & CHALLENGES
8.2.15. STRYKER CORPORATION
8.2.15.1. COMPANY OVERVIEW
8.2.15.2. PRODUCT LIST
8.2.15.3. STRENGTHS & CHALLENGES
8.2.16. TERUMO CORPORATION
8.2.16.1. COMPANY OVERVIEW
8.2.16.2. PRODUCT LIST
8.2.16.3. STRENGTHS & CHALLENGES

　

ページTOPに戻る


　

Summary

KEY FINDINGS
The Europe neurovascular devices/interventional neurology market is evaluated to grow with a CAGR of 5.01% during the forecast years of 2023 to 2032. The geriatric population’s high susceptibility to neurological illnesses, like strokes and vascular disorders, as well as the advent of teleconsultation and telemedicine services, especially in underserved or rural areas, are among the top factors fueling the market growth of the region.
MARKET INSIGHTS
The Europe neurovascular devices/interventional neurology market growth evaluation covers the study of the United Kingdom, Spain, Poland, Belgium, Germany, France, Italy, and Rest of Europe. The French government has taken significant strides in addressing specific neurological conditions, such as epilepsy, Alzheimer’s disease, and Parkinson’s disease, through various national initiatives. These initiatives aim to advance research, diagnosis, and therapy for these disorders while also providing support to patients as well as their families.
A key endeavor is the upcoming Booster Program, including the NeuroTechnologies Program, set to be launched by Inserm in France in 2023. The government has also allocated substantial funding to drive brain research, encompassing basic neuroscience research, translational research, and clinical trials. Furthermore, the French government supports the National Multidisciplinary Consortium for 119 Certified Research Teams in Autism and Neurodevelopmental Disorders as part of its commitment to the National Autism and Neurodevelopmental Disorders Strategy. Patients with neurological conditions receive essential services, with a focus on improving functional outcomes and quality of life through funding for neurorehabilitation facilities and programs. Hence, such factors are set to propel the region’s market growth during the forecast period.
COMPETITIVE INSIGHTS
Some of the main companies operating in the market are Phenox Inc, Acandis GmbH, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. GOVERNMENT INITIATIVES TO CREATE AWARENESS ABOUT NEUROVASCULAR DISEASES
2.5.2. EARLY DETECTION OF ARTERIOVENOUS MALFORMATION (AVM)
2.5.3. THROMBECTOMY IMPROVES PATIENT OUTCOMES AND REDUCES DISABILITY RATE
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SIGNIFICANT RISE IN INCIDENCE OF NEUROVASCULAR CONDITIONS
3.1.2. PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES
3.1.3. GERIATRIC POPULATION’S VULNERABILITY TO NEUROVASCULAR DISEASES
3.1.4. UNDERLYING DISEASES ARE A RISK FACTOR FOR NEUROVASCULAR DISEASES
3.2. KEY RESTRAINTS
3.2.1. EXORBITANT COSTS OF NEUROVASCULAR DEVICES
3.2.2. LACK OF TRAINED NEUROSURGEONS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR UNITED KINGDOM
4.4. MARKET CONCENTRATION ANALYSIS
4.5. VALUE CHAIN ANALYSIS
5. MARKET BY PRODUCT
5.1. EMBOLIZATION DEVICES
5.1.1. EMBOLIC COILS
5.1.1.1. COATED DETACHABLE COILS
5.1.1.2. BARE DETACHABLE COILS
5.1.2. COIL ASSIST STENT
5.1.3. CLIPPINGS
5.1.4. COIL ASSIST BALLOON
5.2. ACCESSORY DEVICES
5.2.1. MICROCATHETERS
5.2.2. MICRO GUIDEWIRES
5.3. REVASCULARIZATION DEVICES
5.3.1. CAROTID ARTERY STENTS
5.3.2. FLOW DIVERSION STENTS
5.4. THROMBECTOMY DEVICES
5.4.1. CLOT RETRIEVAL DEVICES
5.4.2. SUCTION AND ASPIRATION DEVICES
5.4.3. SNARES
5.5. EMBOLIC PROTECTION DEVICES
5.5.1. BALLOON OCCLUSION DEVICES
5.5.2. DISTAL FILTER DEVICES
6. MARKET BY APPLICATION
6.1. ANEURYSM
6.2. ISCHEMIC STROKE
6.3. STENOSIS
6.4. ARTERIOVENOUS MALFORMATION (AVM)
6.5. OTHER APPLICATIONS
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. MARKET SIZE & ESTIMATES
7.1.2. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET DRIVERS
7.1.3. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET CHALLENGES
7.1.4. EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET REGULATORY FRAMEWORK
7.1.5. KEY PLAYERS IN EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET
7.1.6. COUNTRY ANALYSIS
7.1.6.1. UNITED KINGDOM
7.1.6.1.1. UNITED KINGDOM NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.2. GERMANY
7.1.6.2.1. GERMANY NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.3. FRANCE
7.1.6.3.1. FRANCE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.4. ITALY
7.1.6.4.1. ITALY NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.5. SPAIN
7.1.6.5.1. SPAIN NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.6. POLAND
7.1.6.6.1. POLAND NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.7. BELGIUM
7.1.6.7.1. BELGIUM NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
7.1.6.8. REST OF EUROPE
7.1.6.8.1. REST OF EUROPE NEUROVASCULAR DEVICES/INTERVENTIONAL NEUROLOGY MARKET SIZE & OPPORTUNITIES
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIPS & AGREEMENTS
8.1.4. BUSINESS EXPANSIONS & DIVESTITURES
8.2. COMPANY PROFILES
8.2.1. ACANDIS GMBH
8.2.1.1. COMPANY OVERVIEW
8.2.1.2. PRODUCT LIST
8.2.2. ASAHI INTECC
8.2.2.1. COMPANY OVERVIEW
8.2.2.2. PRODUCT LIST
8.2.3. BALT
8.2.3.1. COMPANY OVERVIEW
8.2.3.2. PRODUCT LIST
8.2.4. B BRAUN MELSUNGEN AG
8.2.4.1. COMPANY OVERVIEW
8.2.4.2. PRODUCT LIST
8.2.4.3. STRENGTHS & CHALLENGES
8.2.5. INTEGER HOLDINGS CORPORATION
8.2.5.1. COMPANY OVERVIEW
8.2.5.2. PRODUCT LIST
8.2.5.3. STRENGTHS & CHALLENGES
8.2.6. JOHNSON & JOHNSON (CERENOVUS)
8.2.6.1. COMPANY OVERVIEW
8.2.6.2. PRODUCT LIST
8.2.6.3. STRENGTHS & CHALLENGES
8.2.7. KANEKA CORPORATION
8.2.7.1. COMPANY OVERVIEW
8.2.7.2. PRODUCT LIST
8.2.8. MEDTRONIC INC
8.2.8.1. COMPANY OVERVIEW
8.2.8.2. PRODUCT LIST
8.2.8.3. STRENGTHS & CHALLENGES
8.2.9. MEMRY CORPORATION
8.2.9.1. COMPANY OVERVIEW
8.2.9.2. PRODUCT LIST
8.2.10. MICROPORT SCIENTIFIC CORPORATION
8.2.10.1. COMPANY OVERVIEW
8.2.10.2. PRODUCT LIST
8.2.10.3. STRENGTHS & CHALLENGES
8.2.11. PENUMBRA INC
8.2.11.1. COMPANY OVERVIEW
8.2.11.2. PRODUCT LIST
8.2.12. PHENOX INC
8.2.12.1. COMPANY OVERVIEW
8.2.12.2. PRODUCT LIST
8.2.12.3. STRENGTHS & CHALLENGES
8.2.13. RAPID MEDICAL
8.2.13.1. COMPANY OVERVIEW
8.2.13.2. PRODUCT LIST
8.2.13.3. STRENGTHS & CHALLENGES
8.2.14. SENSOME
8.2.14.1. COMPANY OVERVIEW
8.2.14.2. PRODUCT LIST
8.2.14.3. STRENGTHS & CHALLENGES
8.2.15. STRYKER CORPORATION
8.2.15.1. COMPANY OVERVIEW
8.2.15.2. PRODUCT LIST
8.2.15.3. STRENGTHS & CHALLENGES
8.2.16. TERUMO CORPORATION
8.2.16.1. COMPANY OVERVIEW
8.2.16.2. PRODUCT LIST
8.2.16.3. STRENGTHS & CHALLENGES

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

Inkwood Research社の
Fatal error: Uncaught TypeError: Cannot access offset of type string on string in /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/58b4bde6a9738f3389cd7dea7f4ef5c62fdc6c54_0.file.auto_report.tpl.php:571 Stack trace: #0 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_resource_base.php(123): content_68a805fa34b2e0_16717164() #1 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_compiled.php(114): Smarty_Template_Resource_Base->getRenderedTemplateCode() #2 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(216): Smarty_Template_Compiled->render() #3 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(385): Smarty_Internal_Template->render() #4 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/f20300271f4eb0fb4a2cf788aaabb06be5646d19_0.file.frame-FULL.tpl.php(278): Smarty_Internal_Template->_subTemplateRender() #5 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_resource_base.php(123): content_68a805fa26a288_46622063() #6 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_template_compiled.php(114): Smarty_Template_Resource_Base->getRenderedTemplateCode() #7 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_template.php(216): Smarty_Template_Compiled->render() #8 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_templatebase.php(238): Smarty_Internal_Template->render() #9 /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/libs/sysplugins/smarty_internal_templatebase.php(134): Smarty_Internal_TemplateBase->_execute() #10 /var/www/vhosts/dri.co.jp/httpdocs/auto/show_report.php(776): Smarty_Internal_TemplateBase->display() #11 {main} thrown in /var/www/vhosts/dri.co.jp/httpdocs/PHPLibs/Smarty/templates_c/58b4bde6a9738f3389cd7dea7f4ef5c62fdc6c54_0.file.auto_report.tpl.php on line 571